HRGN Harvard Apparatus Regenerative Technology, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1563665 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY35.1%
TTM net income YoY1.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin7.5%
Operating margin-643.0%
Net margin-642.0%
FCF margin—
EBITDA margin-642.6%
Returns
ROE-621.0%
ROA-225.6%
ROIC (approx.)—
Asset turnover0.35x
Leverage & solvency
Liabilities / assets83.5%
Debt / equity0.00x
Current ratio0.87x
Interest coverage-269.00x
Cash quality & payout
Operating cash flow / net income0.43x
Accruals ratio-127.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $145,000 | $414,000 | $226,000 | $219,000 | $123,000 | $317,000 | $45,000 | $258,000 |
| Cost of revenue | $133,000 | $391,000 | $206,000 | $199,000 | $112,000 | $302,000 | $33,000 | $175,000 |
| Gross profit | $12,000 | $23,000 | $20,000 | $20,000 | $11,000 | $15,000 | $12,000 | $83,000 |
| R&D expense | $218,000 | $948,000 | $563,000 | $700,000 | $655,000 | $697,000 | $601,000 | $271,000 |
| SG&A expense | $1.24M | $751,000 | $1.04M | $986,000 | $1.04M | $1.15M | $1.07M | $1.08M |
| Operating income | -$1.46M | -$1.69M | -$1.61M | -$1.70M | -$1.71M | -$1.83M | -$1.67M | -$1.36M |
| Interest expense | $13,000 | $8,000 | $2,000 | $1,000 | $2,000 | $3,000 | $2,000 | $2,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$1.46M | -$1.70M | -$1.60M | -$1.69M | -$1.70M | -$1.82M | -$1.66M | -$1.34M |
| EBITDA | -$1.46M | -$1.69M | -$1.60M | -$1.70M | -$1.71M | -$1.83M | -$1.67M | -$1.36M |
| EPS (basic) | -0.08 | -0.10 | -0.09 | — | -0.10 | -0.11 | -0.10 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.85M | $351,000 | $419,000 | $1.35M | $1.32M | $786,000 | $1.73M | $2.49M |
| Receivables | $18,000 | $9,000 | $16,000 | $16,000 | $3,000 | $5,000 | $4,000 | $231,000 |
| Inventory | $0 | $0 | $15,000 | $16,000 | $22,000 | $27,000 | $48,000 | $80,000 |
| Current assets | $2.30M | $789,000 | $873,000 | $1.83M | $1.63M | $1.12M | $2.30M | $3.23M |
| PP&E, net | $3,000 | $4,000 | $5,000 | $6,000 | $7,000 | $8,000 | $9,000 | $11,000 |
| Total assets | $3.17M | $1.69M | $1.80M | $2.68M | $2.55M | $2.14M | $3.42M | $4.44M |
| Current liabilities | $2.65M | $3.04M | $1.65M | $1.53M | $876,000 | $1.23M | $1.20M | $1.02M |
| Total liabilities | $2.65M | $3.06M | $1.71M | $1.62M | $992,000 | $1.38M | $1.37M | $1.22M |
| Shareholders' equity | $522,000 | -$1.38M | $92,000 | $1.06M | $1.55M | $761,000 | $2.05M | $3.22M |
| Shares outstanding | 20.09M | 17.58M | 17.58M | 17.58M | 17.17M | 15.92M | 15.92M | 15.92M |
| Cash flow statement | ||||||||
| Operating cash flow | -$621,000 | -$569,000 | -$937,000 | -$664,000 | -$1.47M | -$941,000 | -$758,000 | -$1.12M |
| Financing cash flow | $2.12M | — | — | $700,000 | $2.00M | $0 | $0 | $0 |
| Depreciation & amortization | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $2,000 | $2,000 |
| Stock-based compensation | $700,000 | $200,000 | $632,000 | $493,000 | $500,000 | $500,000 | $485,000 | $708,000 |
Free plan shows the latest 8 periods; Pro shows all 59 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.